Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical firm into discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic possibility, on August 5, 2021 announced the pricing of its initial public offering of 18,200,000 shares of common stock at a price to the public of $17.00 per share. The gross earnings to Adagio from the offering, prior to removing the underwriting discounts and commissions and offering expenses, are anticipated to be $309.4 million. The entire shares are being offered by Adagio. Additionally, Adagio has approved the underwriters a 30-day option to buy up to an extra 2,730,000 shares of its common stock at the IPO offering price minus the commissions and underwriting discounts.
The shares are billed to start trading on the Nasdaq Global Market under the inscription “ADGI” on August 6, 2021, and the offering is billed to close on August 10, 2021, based to customary closing conditions.
Morgan Stanley, Stifel, Jefferies and Guggenheim are serving as joint book-running managers for the offering.
The offering is being made only via a prospectus. A copy of the final prospectus, when available, may be gotten via: Morgan Stanley & Co. LLC, 180 Varick Street, 2nd floor, New York, NY 10014, Attention: Prospectus Department; Jefferies LLC, 520 Madison Avenue, 2nd Floor, New York, NY 10022, Attention: Equity Syndicate Prospectus Department, by telephone at 877-821-7388 or via email at email@example.com; Nicolaus & Company, Incorporated at Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, via telephone at 415-364-2720, or via email at firstname.lastname@example.org; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, via telephone at 212-518-9544, or via email at GSEquityProspectusDelivery@guggenheimpartners.com
A registration statement about these securities has been submitted with, and declared effective by, the Securities and Exchange Commission. This press release shall not be taken as an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful before registration or qualification under the securities laws of any such state or jurisdiction.